Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Column Group
Biotech
Cell therapy biotech bags $102M to fund phase 3 epilepsy plans
Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.
Gabrielle Masson
Apr 3, 2025 1:22pm
Eikon remains in megaround mode with $350M series D
Feb 26, 2025 9:40am
Judo throws down $100M to knock out kidney disease
Oct 7, 2024 10:42am
Amgen-partnered Plexium snags $102M for protein degraders
Feb 23, 2022 8:00am
Appia Bio aims for new off-the-shelf CAR-T with $52M raise
May 11, 2021 5:15am
Remix debuts with $81M to 'reprogram' disease-causing RNA
Dec 8, 2020 7:15am
